FLEMINGTON, N.J.--(BUSINESS WIRE)--Sept. 13, 2006--NovaDel Pharma (AMEX: NVD) today announced the two latest additions to its pipeline of oral spray drug development candidates. NovaDel's new programs are focused on treating disorders of the central nervous system (CNS), with Tizanidine Oral Spray (formerly NVD 422) for spasticity and Ropinirole Oral Spray (formerly NVD 434) for Parkinson's disease. NovaDel has completed development of the new oral formulations for both compounds and is currently finalizing the preclinical characterization of these oral sprays.
